Table I.
Characteristics of the included trials and participants.
| First author (year) | Design | Follow-up | Age (years) GSH/Control | Participants (males/females) GSH/Control | Intervention Route, dose, frequency | Outcomes | (Refs.) |
|---|---|---|---|---|---|---|---|
| Hauser (2009) | RCT | 4 w | 62.6+7.9/ 65.9+12.6 | (5/5)/(6/4) | Intravenous push, 1400 mg, Qd | A; B; C; E | (10) |
| Mischley (2017) | RCT | 3 m | 60.9+11/ 60.9+11 | 11; 14/14 | Intranasal administration, 300 mg or 600 mg, Qd | A; B; C | (11) |
| Mischley (2015) | RCT | 3 m | - | 10; 10/10 | Intranasal administration, 300 mg or 600 mg, Qd | A; B; C; E | (12) |
| Bao (2018) | RCT | 4 m | 64.6+8.2/ 65.1+9.6 | (56/44)/(55/45) | Intravenous drip, 600 mg, Bid | A; B; C; D | (14) |
| Bao (2003) | RCT | 6 w | 61.41+9.68/ 58.87+7.94 | (14/16)/(16/14) | Intravenous drip, 600 mg, Bid | D | (15) |
| Hu (2019) | RCT | 21 d | 66.8+6.9/ 70.7+7 | (17/15)/(18/13) | Intravenous drip, 1200-1400 mg, Qd | A; B; C; D; E | (16) |
| Zhang (2005) | RCT | 4 m | 56+4.5/ 57+4.9 | (12/7)/(11/8) | Intravenous drip, 600 mg, Bid | D | (17) |
GSH, reduced glutathione; RCT, randomized controlled trial; Bid, bis in die; Qd, quaque die; w, weeks; m, months; d, days; UPDRS, Unified Parkinson's Disease Rating Scale; A, UPDRS I; B, UPDRS II; C, UPDRS III; D, glutathione peroxidase; E, adverse events; m, months; w, weeks.